Topic 414 : synthetic biology gene circuits for cancer therapy
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91021C00026
- Awardee
-
Senti Biosciences, Inc. UEI FDEFJM4MKC63
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,999,993
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proprosals Pre-Solicitation · PHS20211 · Posted Jul 9, 2020
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proprosals Solicitation · Posted Jul 28, 2020
- Contract value 100% obligated
- $1,999,993.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 5 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- South San Francisco, CA 94080, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,999,993 |
About this award
This firm fixed price definitive contract was awarded by the National Institutes of Health National Cancer Institute to Senti Biosciences, Inc., a self-certified small disadvantaged business, for $1,999,993. The contract addresses Topic 414 from the fiscal year 2021 Small Business Innovation Research Program solicitation issued by the Department of Health and Human Services, which sought proposals for synthetic biology gene circuits for cancer therapy. The place of performance is South San Francisco, California and the period of performance concludes on July 31, 2023. This award is set aside for total small businesses and aims to advance the National Cancer Institute's mission of cancer research through the development of innovative gene therapy approaches for treating cancer.
Quick answers
Who was awarded contract 75N91021C00026?
75N91021C00026 was awarded to Senti Biosciences, Inc. by National Cancer Institute (National Institutes of Health) on August 1, 2021.
How much is contract 75N91021C00026 worth?
The government has obligated $1,999,993 on 75N91021C00026.
Was contract 75N91021C00026 competed?
The extent of competition for 75N91021C00026 was full and open competition after exclusion of sources. The government received 5 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award